What is Nvigen?
NVIGEN is a biotechnology firm at the vanguard of personalized medicine, specializing in the development of advanced assays that unify DNA, RNA, protein, and cellular information. Leveraging molecularly engineered nanoparticles, NVIGEN offers sophisticated diagnostic tools such as the NVIGEN X Cancer Precision Profiling Test. These innovations are geared towards empowering the biotech community to enhance the precision of cancer detection, patient monitoring, and therapeutic strategies. The company's core mission involves advancing biomarker profiling, precision diagnostics, and T-cell therapy to address critical health challenges including aging, cancer, and cardiovascular diseases. NVIGEN's dedication to pioneering research and collaborative efforts aims to facilitate more effective and efficient healthcare solutions.
How much funding has Nvigen raised?
Nvigen has raised a total of $1.2M across 2 funding rounds:
Series B
$1.1M
Debt
$53K
Series B (2014): $1.1M, investors not publicly disclosed
Debt (2021): $53K led by PPP
What's next for Nvigen?
With the recent influx of substantial expansion capital, Nvigen is strategically positioned to accelerate its research and development initiatives and broaden the market penetration of its precision profiling technologies. The company's focus on integrating multi-omic data through its proprietary nanoparticle technology suggests a future emphasis on refining diagnostic accuracy and developing targeted therapies. This enterprise-level backing is likely to fuel further innovation in biomarker discovery and the enhancement of personalized treatment protocols, solidifying Nvigen's role in advancing precision medicine and addressing complex health conditions.
See full Nvigen company page
